PharmaEngine   Report issue

For profit Phase 1 Phase 2
Founded: Taipei Taiwan (2003)

Organization Overview

First Clinical Trial
2004
NCT00219648
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

PharmaEngine

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Colorectal Neoplasms (Phase 1)

Esophageal Neoplasms (Phase 2)

Head and Neck Neoplasms (Phase 2)

Lung Diseases, Obstructive (Phase 2)

Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Rectal Neoplasms (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Stomach Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 10
  • # of Trial APIs: 9